Preemptive Pharmacogenomic Testing
Preemptive Pharmacogenomic Testing is a form of pharmacogenomic testing that involves the prospective genotyping of individuals for pharmacogenomic variants prior to the prescription of relevant medications, enabling future drug selection and dosing decisions based on genetic profile.
28
Publications
2K
Citations
347
Authors
113
Institutions
Publications per year
2017–2026
16
Parents
28
Cathelijne H. van der Wouden, Anne Cambon‐Thomsen, Erika Cecchin et al. · Clinical Pharmacology & Therapeutics · 2016 · 292 citations · Full text
Preemptive Pharmacogenomic Testing for Precision Medicine
Yuan Ji, Jennifer M. Skierka, Joseph H. Blommel et al. · Journal of Molecular Diagnostics · 2016 · 196 citations · Full text
Omri Gottesman, Stuart A. Scott, Stephen B. Ellis et al. · Clinical Pharmacology & Therapeutics · 2013 · 154 citations · Full text
1–5 of 28
347
3
h-index
3
h-index
3
h-index
3
h-index
3
h-index
1–5 of 347
113
Mayo Clinic in Florida
Jacksonville, United States
4 h-index
37 publications
3.1K citations

St. Jude Children's Research Hospital
Memphis, United States
3 h-index
19 publications
3K citations

Uppsala University
Uppsala, Sweden
3 h-index
9 publications
765 citations

Leiden University Medical Center
Leiden, The Netherlands
3 h-index
16 publications
1.8K citations
University of Chicago
Chicago, United States
3 h-index
28 publications
1.8K citations
Mayo Clinic
Rochester, United States
3 h-index
41 publications
4.9K citations
WinnMed
Decorah, United States
3 h-index
9 publications
682 citations
Mayo Clinic in Arizona
Scottsdale, United States
2 h-index
56 publications
3.9K citations
1–8 of 113
CPT · 9 publications · 929 citations
9
h-index
2 publications · 56 citations
2
h-index
GIM · 2 publications · 146 citations
2
h-index
1 publications · 128 citations
1
h-index
1 publications · 63 citations
1
h-index
1–5